Skip to main content
. 2023 Aug 14;13:1141876. doi: 10.3389/fonc.2023.1141876

Table 3.

Immune checkpoint inhibitors in BRAF-mutant NSCLC.

Trial Study Design ICI Number of patient/lines mPFS (s) mOS (months) ORR (%
Dudnek Retrospective 10 Pembrolizumab
11 Nivolumab
1 Atezolizumab
12 V600
10 non-V600
3.7
4.1
NA
NA
25
33
Mazieres Retrospective ICI 43 3.1 13.6 24
Guisier Retrospective
Offin Retrospective 10 V600
36 nonV600
NA
NA
NA
28.8
10
22
Hellman Phase 1/1b Cobimetinib and Atezolizumab 28 NSCLC 29% 13.2 18

NA, Not applicable.